Hematologic Cancer Fusion Analysis
GTR Test Accession: Help GTR000597220.2
Last updated in GTR: 2023-01-04
Last annual review date for the lab: 2023-07-14 LinkOut
At a Glance
Therapeutic management
Hematologic neoplasm
ABL1 (9q34.12), ABL2 (1q25.2), AFDN (6q27), AICDA (12p13.31), ALK (2p23.2-23.1), ...
Molecular Genetics - RNA analysis: Next-Generation (NGS)/Massively parallel sequencing (MPS)
Patients who have been diagnosed to have hematologic malignancy
Not provided
Not provided
Ordering Information
Offered by: Help
Institute for Genomic Medicine (IGM) Clinical Laboratory
View lab's website
View lab's test page
Test short name: Help
Heme Archer
Manufacturer's name: Help
FusionPlex Pan-Heme Panel
Specimen Source: Help
Who can order: Help
  • Genetic Counselor
  • Health Care Provider
  • Licensed Physician
  • Nurse Practitioner
Test Order Code: Help
Lab contact: Help
Kathleen Schieffer, PhD, FACMG, Lab Director
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
Samples can be accepted 7 days a week (Monday - Sunday). All samples must be labeled with minimum of two patient identifying information (e.g. Patient Name and Date of Birth). Please Submit disease involved sample with a completed requisition form and a pathology report documenting the diagnosis. Please refer to …
View more
Order URL
Test development: Help
Manufactured (research use only; not FDA-reviewed)
Informed consent required: Help
Pre-test genetic counseling required: Help
Post-test genetic counseling required: Help
Recommended fields not provided:
Conditions Help
Total conditions: 1
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 147
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Total methods: 1
Method Category Help
Test method Help
Instrument *
RNA analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose: Help
Therapeutic management
Target population: Help
Patients who have been diagnosed to have hematologic malignancy
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
VUS and novel variants will be interpreted by trained variant analysis team member and a lab director using the current ACMG variant classification criteria.

Are family members with defined clinical status recruited to assess significance of VUS without charge? Help

Will the lab re-contact the ordering physician if variant interpretation changes? Help
Yes. No systemic re-evaluation of previously reported variants/findings are currently performed. However, if the same variant/finding is identified in another patient and current assessment results in change in variant classification/interpretation, then the laboratory will recontact the ordering provider and issue an updated report.
Recommended fields not provided:
Technical Information
Test Comments: Help
CPT code updated 2023 to 81456
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
This assay detects gene fusions involving listed genes as a fusion gene partner. >99% of gene fusions involving these gene partners are detected by this assay if sample contains minimum blast/tumor % content requirement for this test (10% for fresh/frozen sample; 25% for FFPE sample).
Proficiency testing (PT):
Is proficiency testing performed for this test? Help

Method used for proficiency testing: Help
Formal PT program

PT Provider: Help
College of American Pathologists, CAP
Laboratory's policy on reporting novel variations Help
Unusual or clinically significant novel variants will be communicated to the ordering provider via telephone call or email communication.
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Category: Not Applicable
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.